Skip to main content
2025 IDWeek Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Session Icons
Live Streamed
Live Streamed
On Demand
On Demand
View Session Discussion + Q&A

Adult ID

Global ID

Pediatric ID
Session Type: Symposium

211 - The Many Facets of Clinical Breakpoints: Impact of MIC, AMR and Dosing on Outcomes

Wednesday, October 22, 2025
10:30 AM - 11:45 AM US ET
Location: B312-B313

Live Streamed On Demand
CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

    Moderator(s)

  • David Gaston, MD PhD

    Assistant Professor, Medical Director (Molecular Infectious Disease Laboratory)
    Vanderbilt University Medical Center
    Nashville, TN, United States

  • JL

    James Lewis, II, PharmD, FIDSA

    Infectious Diseases Pharmacy Programs Supervisor
    Oregon Health & Science University
    Portland, OR, United States

    • Faculty(s)

  • AB

    Alexandra Bryson, Ph.D., D(ABMM)

    Associate Director of Clinical Microbiology, Assistant Professor of Pathology
    Pathology
    Virginia Commonwealth University Health System
    Richmond, Virginia, United States

  • Andrew Fratoni, PharmD

    Associate Director, Clinical and Laboratory Studies
    Center for Anti-Infective Research and Development
    Hartford Hospital
    Hartford, CT, United States

  • JL

    James Lewis, II, PharmD, FIDSA

    Infectious Diseases Pharmacy Programs Supervisor
    Oregon Health & Science University
    Portland, OR, United States

Disclosure(s):
David C. Gaston, MD PhD: American Society of Microbiology: Honoraria; Biomerieux/Biofire diagnositcs: Honoraria; DiaSorin: Honoraria; QuidelOrtho: Honoraria; Roche Diagnostics: Honoraria; T2Biosystems: Grant/Research Support
James S. Lewis, PharmD, FIDSA, II: AbbVie Inc: Advisor/Consultant, Honoraria; SHIONOGI and CO., LTD.: Advisor/Consultant, Honoraria
Alexandra L. Bryson, Ph.D., D(ABMM): No financial relationships to disclose.
Andrew J. Fratoni, PharmD: Insight RX, Inc: Grant/Research Support; Qpex Biopharma Inc.: Grant/Research Support

Learning Objectives:

At the conclusion of this session, participants will be able to:
  • describe how clinical breakpoints are set for antimicrobial agents;
  • describe how methods can impact antimicrobial susceptibility testing results;
  • identify how the MIC, antimicrobial resistance and dosing impact clinical breakpoints.

Presentations:

  • 10:30 AM - 10:55 AM US ET
    What Makes a Good Breakpoint?

    Speaker: James S. Lewis, II, PharmD, FIDSA – Oregon Health & Science University

  • 10:55 AM - 11:20 AM US ET
    Should I Hang My Hat on This Antimicrobial Susceptibility Testing Result?

    Speaker: Alexandra L. Bryson, Ph.D., D(ABMM) – Virginia Commonwealth University Health System

  • 11:20 AM - 11:45 AM US ET
    What Matters Most? MIC, AMR or Dosing?

    Speaker: Andrew J. Fratoni, PharmD – Hartford Hospital